OneMedNet is a Nasdaq Capital Market imaging-data vendor that has already shut its old hospital-exchange product and is trying to become a subscription seller of regulatory-grade real-world imaging to drugmakers and device firms. The second-quarter print tests whether that pivot is a commercial business or still a project shop living on related-party equity. Management states that cash is not enough to fund the next year, and that those conditions raise substantial doubt about the ability to continue as a going concern. The equity is therefore a residual claim on a conversion story that has not yet shown up in recognized revenue.
Recognized sales for the quarter were $292 thousand. That figure is up from $155 thousand a year earlier, almost entirely from one-off data deliveries after the BEAM subscription line fell to zero. Cost of those deliveries still ran far above the invoice. The quarter produced a gross loss of $565 thousand. The operating loss approached $2 million. Cash ended June at $358 thousand against several million of liabilities. The April Nasdaq bid-price notice and the July standby equity line with Yorkville are the same story in different wrappers. The franchise is funding a Palantir-branded rebuild by issuing stock into a sub-dollar tape.
The next several months resolve a single question. Does the Foundry platform convert the claimed pipeline into recurring contracts large enough to cover cash burn, or does the bid-price clock and the going-concern paragraph force another recapitalization that leaves common as a thinner residual?